Zastosowanie desloratadyny w monoterapii i w terapii łączonej w leczeniu alergicznego nieżytu nosa Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2016
Słowa kluczowe:
desloratadyna, furoinian mometazonu, alergiczny nieżyt nosa
##plugins.themes.bootstrap3.article.main##
Abstrakt
Leki antyhistaminowe są jednymi z najczęściej stosowanych leków w alergicznym nieżycie nosa. Desloratadyna należy do grupy nowoczesnych preparatów drugiej generacji, które są pozbawione działania sedacyjnego na ośrodkowy układ nerwowy. Ponadto nie wpływa na zmianę masy ciała i charakteryzuje się wysokim profilem bezpieczeństwa. Lek ten skutecznie redukuje objawy alergicznego nieżytu nosa u dzieci i dorosłych. Addycyjny efekt terapeutyczny desloratadyny z glikokortykosteroidami donosowymi jest obiecujący, ale wymaga dalszych badań.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Sokołowski, R. (2016). Zastosowanie desloratadyny w monoterapii i w terapii łączonej w leczeniu alergicznego nieżytu nosa . Medycyna Faktów , 9(1(30), 36-40. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2267
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Benninger M.S., Benninger R.M.: The impact of allergic rhinitis on sexual activity, sleep, and fatigue. Allergy Asthma Proc. 2009; 30(4): 358-365.
2. Blaiss M.S.: Pediatric allergic rhinitis: physical and mental complications. Allergy Asthma Proc. 2008; 29(1): 1-6.
3. Bloom M., Staudinger H., Herron J.: Safety of desloratadine syrup in children. Curr. Med. Res. Opin. 2004; 20(12): 1959-1965.
4. Bousquet J., Khaltaev N., Cruz A.A. et al.: Allergic Rhinitis and its impact of Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63(supl. 86): 8-160.
5. Cavanah D.K., Casale T.B.: Histamine. W: Kaliner M.A., Metcalfe D.D. (red.): The Mast Cell in Health and Disease. Marcel Dekker, Inc. 1993: 321-342, seria: Lung Biology in Health and Disease.
6. Chervinsky P., Georgitis J., Banov C. et al.: Once daily loratadine versus astemizole once daily. Ann. Allergy 1994; 73: 109-113.
7. Anolik R.; Mometasone Furoate Nasal Spray With Loratadine Study Group: Clinical benefits of combination treatment with mometasone furoate nasal spray and loratadine vs monotherapy with mometasone furoate in the treatment of seasonal allergic rhinitis. Ann. Allergy Asthma Immunol. 2008; 100(3): 264-271.
8. Dinges D.F., Pack F., Williams K. et al.: Cumulative sleepiness, mood disturbance, and psychomotor vigilance performance decrements during week of sleep restricted to 4-5 hours per night. Sleep. 1997; 20: 267-277.
9. Gelardi M., Russo C., Fiorella M.L. et al.: When allergic rhinitis is not only allergic. Am. J. Rhinol. Allergy 2009; 23: 312-315.
10. Genovese A., Patella V., De Crescenzo G. et al.: Loratadine and desethoxylcarbonyl-loratadine inhibit the immunological release of mediators from human Fc epsilon RI+ cells. Clin. Exp. Allergy 1997; 27(5): 559-567.
11. Gupta S., Khalilieh S., Kantesaria B. et al.: Pharmacokinetics of desloratadine in children between 2 and 11 years of age. Br. J. Clin. Pharmacol. 2007; 63(5): 534-540.
12. Holmberg K., Tonnel A.B., Dreyfus I. et al.: Desloratadine relieves nasal congestion and improves quality-of-life in persistent allergic rhinitis. Allergy 2009; 64(11): 1663-1670.
13. Kaditis A.G., Finder J., Alexopoulos E.L. et al.: Sleep-disordered breathing in 3,680 Greek children. Pediatr. Pulmonol. 2004; 37: 499-509.
14. Kirmaz C., Aydemir O., Bayrak P. et al.: Sexual dysfunction in patients with allergic rhinoconjunctivitis. Ann. Allergy Asthma Immunol. 2005; 95(6): 525-529.
15. Kmiecik B., Skotny A., Batycka M. et al.: Wpływ stresu oksydacyjnego na procesy regeneracji tkankowej. Polim. Med. 2013; 43(3): 191-197.
16. Kripke D.F., Simons R.N., Garfinkel L., Hammond E.C.: Short and long sleep and sleeping pills. Is increased mortality associated? Arch. Gen. Psychiatr. 1979; 36(1): 103-116.
17. Léger D., Annesi-Maesano I., Carat F. et al.: Allergic rhinitis and its consequences on quality of sleep: An unexplored area. Arch. Intern. Med. 2006; 166(16): 1744-1748 .
18. Lieberman P.: The basics of histamine biology. Ann. Allergy Asthma Immunol. 2011; 106(supl. 2): S2-5.
19. Mir E., Panjabi C., Shah A.: Impact of allergic rhinitis in school going children. Asia Pac. Allergy. 2012; 2(2): 93-100.
20. Mullol J., de Borja Callejas F., Martínez-Antón M.A. et al.: Mometasone and desloratadine additive effect on eosinophil survival and cytokine secretion from epithelial cells. Respir. Research 2011; 12(1): 23.
21. Mygindin D.: Epidemiology of allergic rhinitis. Pediatr. Allergy Immunol. 1996; 7(supl. 9): 57-62.
22. Ng D.K., Chan C.H., Kwok K.L., Cheung J.M.: Allergic rhinitis as a risk factor for habitual snoring in children. Chest. 2005; 127: 2285-2286.
23. Onrust S.V., Lamb H.M.: Mometasone furoate. A review of its intranasal use in allergic rhinitis. Drugs 1998; 56(4): 725-745.
24. Orthen-Gambill N.: Antihistaminic drugs increase feeding, while histidine suppresses feeding in rats. Pharmacol. Biochem. Behav. 1988; 31(1): 81-86.
25. Kakumanu S., Glass C., Craig T.: Poor sleep and daytime somnolence in allergic rhinitis: significance of nasal congestion. Am. J. Respir. Med. 2002; 1(3): 195-200.
26. Rolf H., Kjetil H., Olof B. et al.: Morning versus evening dosing of desloratadine in seasonal allergic rhinitis: a randomized controlled study [ISRCTN23032971]. Clin. Mol. Allergy 2005; 3: 3.
27. Sadowska-Woda I., Bieszczad-Bedrejczuk E., Rachel M.: Influence of desloratadine on selected oxidative stress markers in patients between 3 and 10 years of age with allergic perennial rhinitis. Eur. J. Pharmacol. 2010; 640(1-3): 197-201.
28. Samoliński B., Sybilski A.J., Raciborski F. et al.: Prevalance of rhinitis in Polish population according to the ECAP (Epidemiology of Allergic Disorders in Poland) study. Otolaryngol. Pol. 2009; 63(4): 324-330.
29. Schroeder J.T., Schleimer R.P., Lichtenstein L.M. et al.: Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin. Exp. Allergy [in press].
30. Spicak V., Dab I., Hulhoven R. et al.: Pharmacokinetics and pharmacodynamics of cetirizine in infants and toddlers. Clin. Pharmacol. Ther. 1997; 61: 325-330.
31. Tassinari P., Suárez N.R., Centeno J. et al.: Desloratadine therapy improves allergic rhinitis symptoms in latin american children aged 6 to 12 years. World Allergy Organ. J. 2009; 2(4): 42-48.
32. Tamer M.H. Adham: Treatment of Allergic Rhinitis With Desloratadine: Results of a Multinational Observational Study in the Middle East Gulf Region. World Allergy Organ. J. 2011; 4(8): 130-134.
33. Valk P.J., Van Roon D.B., Simons R.M., Rikken G.: Desloratadine shows no effect on performance during 6 h at 8,000 ft simulated cabin altitude. Aviat. Space Environ. Med. 2004; 75(5): 433-438.
34. Vaziri P., Dang K., Anderson G.H.: Evidence for histamine involvement in the effect of histidine loads on food and water intake in rats. J. Nutr. 1997; 127(8): 1519-1526.
35. Yuksel H., Sogut A., Yilmaz H. et al.: Sleep actigraphy evidence of improved sleep after treatment of allergic rhinitis. Ann. Allergy Asthma Immunol. 2009; 103(4): 290-294.
2. Blaiss M.S.: Pediatric allergic rhinitis: physical and mental complications. Allergy Asthma Proc. 2008; 29(1): 1-6.
3. Bloom M., Staudinger H., Herron J.: Safety of desloratadine syrup in children. Curr. Med. Res. Opin. 2004; 20(12): 1959-1965.
4. Bousquet J., Khaltaev N., Cruz A.A. et al.: Allergic Rhinitis and its impact of Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63(supl. 86): 8-160.
5. Cavanah D.K., Casale T.B.: Histamine. W: Kaliner M.A., Metcalfe D.D. (red.): The Mast Cell in Health and Disease. Marcel Dekker, Inc. 1993: 321-342, seria: Lung Biology in Health and Disease.
6. Chervinsky P., Georgitis J., Banov C. et al.: Once daily loratadine versus astemizole once daily. Ann. Allergy 1994; 73: 109-113.
7. Anolik R.; Mometasone Furoate Nasal Spray With Loratadine Study Group: Clinical benefits of combination treatment with mometasone furoate nasal spray and loratadine vs monotherapy with mometasone furoate in the treatment of seasonal allergic rhinitis. Ann. Allergy Asthma Immunol. 2008; 100(3): 264-271.
8. Dinges D.F., Pack F., Williams K. et al.: Cumulative sleepiness, mood disturbance, and psychomotor vigilance performance decrements during week of sleep restricted to 4-5 hours per night. Sleep. 1997; 20: 267-277.
9. Gelardi M., Russo C., Fiorella M.L. et al.: When allergic rhinitis is not only allergic. Am. J. Rhinol. Allergy 2009; 23: 312-315.
10. Genovese A., Patella V., De Crescenzo G. et al.: Loratadine and desethoxylcarbonyl-loratadine inhibit the immunological release of mediators from human Fc epsilon RI+ cells. Clin. Exp. Allergy 1997; 27(5): 559-567.
11. Gupta S., Khalilieh S., Kantesaria B. et al.: Pharmacokinetics of desloratadine in children between 2 and 11 years of age. Br. J. Clin. Pharmacol. 2007; 63(5): 534-540.
12. Holmberg K., Tonnel A.B., Dreyfus I. et al.: Desloratadine relieves nasal congestion and improves quality-of-life in persistent allergic rhinitis. Allergy 2009; 64(11): 1663-1670.
13. Kaditis A.G., Finder J., Alexopoulos E.L. et al.: Sleep-disordered breathing in 3,680 Greek children. Pediatr. Pulmonol. 2004; 37: 499-509.
14. Kirmaz C., Aydemir O., Bayrak P. et al.: Sexual dysfunction in patients with allergic rhinoconjunctivitis. Ann. Allergy Asthma Immunol. 2005; 95(6): 525-529.
15. Kmiecik B., Skotny A., Batycka M. et al.: Wpływ stresu oksydacyjnego na procesy regeneracji tkankowej. Polim. Med. 2013; 43(3): 191-197.
16. Kripke D.F., Simons R.N., Garfinkel L., Hammond E.C.: Short and long sleep and sleeping pills. Is increased mortality associated? Arch. Gen. Psychiatr. 1979; 36(1): 103-116.
17. Léger D., Annesi-Maesano I., Carat F. et al.: Allergic rhinitis and its consequences on quality of sleep: An unexplored area. Arch. Intern. Med. 2006; 166(16): 1744-1748 .
18. Lieberman P.: The basics of histamine biology. Ann. Allergy Asthma Immunol. 2011; 106(supl. 2): S2-5.
19. Mir E., Panjabi C., Shah A.: Impact of allergic rhinitis in school going children. Asia Pac. Allergy. 2012; 2(2): 93-100.
20. Mullol J., de Borja Callejas F., Martínez-Antón M.A. et al.: Mometasone and desloratadine additive effect on eosinophil survival and cytokine secretion from epithelial cells. Respir. Research 2011; 12(1): 23.
21. Mygindin D.: Epidemiology of allergic rhinitis. Pediatr. Allergy Immunol. 1996; 7(supl. 9): 57-62.
22. Ng D.K., Chan C.H., Kwok K.L., Cheung J.M.: Allergic rhinitis as a risk factor for habitual snoring in children. Chest. 2005; 127: 2285-2286.
23. Onrust S.V., Lamb H.M.: Mometasone furoate. A review of its intranasal use in allergic rhinitis. Drugs 1998; 56(4): 725-745.
24. Orthen-Gambill N.: Antihistaminic drugs increase feeding, while histidine suppresses feeding in rats. Pharmacol. Biochem. Behav. 1988; 31(1): 81-86.
25. Kakumanu S., Glass C., Craig T.: Poor sleep and daytime somnolence in allergic rhinitis: significance of nasal congestion. Am. J. Respir. Med. 2002; 1(3): 195-200.
26. Rolf H., Kjetil H., Olof B. et al.: Morning versus evening dosing of desloratadine in seasonal allergic rhinitis: a randomized controlled study [ISRCTN23032971]. Clin. Mol. Allergy 2005; 3: 3.
27. Sadowska-Woda I., Bieszczad-Bedrejczuk E., Rachel M.: Influence of desloratadine on selected oxidative stress markers in patients between 3 and 10 years of age with allergic perennial rhinitis. Eur. J. Pharmacol. 2010; 640(1-3): 197-201.
28. Samoliński B., Sybilski A.J., Raciborski F. et al.: Prevalance of rhinitis in Polish population according to the ECAP (Epidemiology of Allergic Disorders in Poland) study. Otolaryngol. Pol. 2009; 63(4): 324-330.
29. Schroeder J.T., Schleimer R.P., Lichtenstein L.M. et al.: Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin. Exp. Allergy [in press].
30. Spicak V., Dab I., Hulhoven R. et al.: Pharmacokinetics and pharmacodynamics of cetirizine in infants and toddlers. Clin. Pharmacol. Ther. 1997; 61: 325-330.
31. Tassinari P., Suárez N.R., Centeno J. et al.: Desloratadine therapy improves allergic rhinitis symptoms in latin american children aged 6 to 12 years. World Allergy Organ. J. 2009; 2(4): 42-48.
32. Tamer M.H. Adham: Treatment of Allergic Rhinitis With Desloratadine: Results of a Multinational Observational Study in the Middle East Gulf Region. World Allergy Organ. J. 2011; 4(8): 130-134.
33. Valk P.J., Van Roon D.B., Simons R.M., Rikken G.: Desloratadine shows no effect on performance during 6 h at 8,000 ft simulated cabin altitude. Aviat. Space Environ. Med. 2004; 75(5): 433-438.
34. Vaziri P., Dang K., Anderson G.H.: Evidence for histamine involvement in the effect of histidine loads on food and water intake in rats. J. Nutr. 1997; 127(8): 1519-1526.
35. Yuksel H., Sogut A., Yilmaz H. et al.: Sleep actigraphy evidence of improved sleep after treatment of allergic rhinitis. Ann. Allergy Asthma Immunol. 2009; 103(4): 290-294.